Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to ...
Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting ...
DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Copyright © 2025 Yahoo. All rights reserved.
Date Sources: Live BSE and NSE Quotes Service: TickerPlant | Corporate Data, F&O Data & Historical price volume data: Dion Global Solutions Ltd. BSE Quotes and Sensex are real-time and licensed from ...
Bonus Jul 11, 2025 Jul 11, 2025 May 30, 2025 Bonus Ratio: 1 share(s) for every 2 shares held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback